专题:CAR-T cell therapy research

This cluster of papers focuses on Chimeric Antigen Receptor (CAR) T cell therapy, a form of immunotherapy that uses genetically engineered T cells to target and destroy cancer cells. The papers cover various aspects of CAR T cell therapy, including its application in treating leukemia, lymphoma, and solid tumors, the management of cytokine release syndrome associated with this therapy, and the long-term efficacy and safety of CAR T cell treatment.
最新文献
CAR-engineered cell therapies: current understandings and future perspectives

article Full Text OpenAlex

BACH2 regulates T cell lineage state to enhance CAR T cell function

article Full Text OpenAlex

Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy

article Full Text OpenAlex

Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy

article Full Text OpenAlex

Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010

article Full Text OpenAlex

Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy

article Full Text OpenAlex

Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000–2025)

review Full Text OpenAlex

Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases

article Full Text OpenAlex

CAR-macrophages in solid tumors: promise, progress, and prospects

article Full Text OpenAlex

Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting

article Full Text OpenAlex

近5年高被引文献
Antibody drug conjugate: the “biological missile” for targeted cancer therapy

review Full Text OpenAlex 1387 FWCI136.6592

Immune Checkpoint Inhibitors in Cancer Therapy

review Full Text OpenAlex 1182 FWCI117.8241

Long-term outcomes following CAR T cell therapy: what we know so far

review Full Text OpenAlex 1172 FWCI273.1187

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

article Full Text OpenAlex 1137 FWCI189.4755

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

article Full Text OpenAlex 1125 FWCI115.9406

CAR T cells produced in vivo to treat cardiac injury

article Full Text OpenAlex 1123 FWCI106.6277

Targeting integrin pathways: mechanisms and advances in therapy

review Full Text OpenAlex 1089 FWCI275.0303

Teclistamab in Relapsed or Refractory Multiple Myeloma

article Full Text OpenAlex 1010 FWCI151.7188

Harnessing cytokines and chemokines for cancer therapy

review Full Text OpenAlex 947 FWCI96.7119

Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

article Full Text OpenAlex 894 FWCI84.9673